Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Misdosing Incident Prompts Astellas To Change Muscle Relaxant Succin Name

This article was originally published in PharmAsia News

Executive Summary

A death caused by drug misdosing in Japan has prompted Astellas to change the name for muscle relaxant Succin (suxamethonium) injection. Last November, a patient died after a hospital in Tokushima Prefecture mistakenly administrated Succin to the patient, who was originally prescribed antibacterial Saxizon (hydrocortisone sodium succinate) by Kowa Pharmaceutical. The incident prompted Japan's Ministry of Health, Labor and Welfare to put out a notice to Astellas and nationwide medical facilities. Astellas will now market the drug with its generic name. (Click here for more - Japanese language

You may also be interested in...



Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

Seretide Settlement To Lift Glenmark’s Europe Business

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.

US/India Operation Intercepts Unapproved Drugs, Drug/Device Products

Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.

UsernamePublicRestriction

Register

SC072324

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel